Pfizer begins study of mRNA flu vaccine
Tweet
Share
E-mail
FILE PHOTO: A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration
(Reuters) -Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.
The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.
"The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines," said Kathrin Jansen, head of vaccine research and development at Pfizer.
The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA accepts Teva's drug application for Tourette syndrome therapy in children
- Moderna jumps premarket after Phase 3 trial, Target slides
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Create E-mail Alert Related Categories
FDA, General News, ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
